138 related articles for article (PubMed ID: 32631504)
21. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins).
Huber K; Schemies J; Uciechowska U; Wagner JM; Rumpf T; Lewrick F; Süss R; Sippl W; Jung M; Bracher F
J Med Chem; 2010 Feb; 53(3):1383-6. PubMed ID: 20030343
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
[TBL] [Abstract][Full Text] [Related]
24. Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells.
Tenhunen J; Kučera T; Huovinen M; Küblbeck J; Bisenieks E; Vigante B; Ogle Z; Duburs G; Doležal M; Moaddel R; Lahtela-Kakkonen M; Rahnasto-Rilla M
Biomed Pharmacother; 2021 Jun; 138():111452. PubMed ID: 33684691
[TBL] [Abstract][Full Text] [Related]
25. Sirtuin 6, a possible therapeutic target for type 2 diabetes.
Bae EJ
Arch Pharm Res; 2017 Dec; 40(12):1380-1389. PubMed ID: 29177584
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazin-2(1H)-one derivatives as new potent PB2 inhibitors.
Yang J; Du J; Huang C; Wang T; Huang L; Yang S; Li L
Bioorg Med Chem Lett; 2019 Jul; 29(13):1609-1613. PubMed ID: 31053507
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
28. Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics.
Sociali G; Galeno L; Parenti MD; Grozio A; Bauer I; Passalacqua M; Boero S; Donadini A; Millo E; Bellotti M; Sturla L; Damonte P; Puddu A; Ferroni C; Varchi G; Franceschi C; Ballestrero A; Poggi A; Bruzzone S; Nencioni A; Del Rio A
Eur J Med Chem; 2015 Sep; 102():530-9. PubMed ID: 26310895
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of human histone deacetylase: synthesis and enzyme assay of hydroxamates with piperazine linker.
Chakrabarty S; Jasmine ; Bhadaliya C; Sinha BN; Mahesh A; Bai H; Blond SY; Jayaprakash V
Arch Pharm (Weinheim); 2010 Mar; 343(3):167-72. PubMed ID: 20217840
[TBL] [Abstract][Full Text] [Related]
30. Differential modulation of SIRT6 deacetylase and deacylase activities by lysine-based small molecules.
Sociali G; Liessi N; Grozio A; Caffa I; Parenti MD; Ravera S; Tasso B; Benzi A; Nencioni A; Del Rio A; Robina I; Millo E; Bruzzone S
Mol Divers; 2020 Aug; 24(3):655-671. PubMed ID: 31240519
[TBL] [Abstract][Full Text] [Related]
31. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Tian Y; Xie Z; Liao C
Bioorg Med Chem Lett; 2020 Apr; 30(8):127036. PubMed ID: 32088129
[TBL] [Abstract][Full Text] [Related]
33. A FRET-based assay for screening SIRT6 modulators.
Li Y; You L; Huang W; Liu J; Zhu H; He B
Eur J Med Chem; 2015; 96():245-9. PubMed ID: 25884115
[TBL] [Abstract][Full Text] [Related]
34. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
36. Benzimidazoles as new scaffold of sirtuin inhibitors: green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties.
Yoon YK; Ali MA; Wei AC; Shirazi AN; Parang K; Choon TS
Eur J Med Chem; 2014 Aug; 83():448-54. PubMed ID: 24992072
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a series of hydroximic acid derivatives as potent histone deacetylase inhibitors.
Zhang L; Wang X; Li X; Zhang L; Xu W
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):582-9. PubMed ID: 24059701
[TBL] [Abstract][Full Text] [Related]
39. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
40. A Comprehensive Analysis into the Therapeutic Application of Natural Products as SIRT6 Modulators in Alzheimer's Disease, Aging, Cancer, Inflammation, and Diabetes.
Akter R; Afrose A; Rahman MR; Chowdhury R; Nirzhor SSR; Khan RI; Kabir MT
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
